News In Brief
This article was originally published in The Silver Sheet
Three former Synthes executives sentenced to prison time for shipping adulterated devices to market; FDA pushes Invacare to sign consent decree.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.